OClawVPS.com
Kuros Biosciences
Edit

Kuros Biosciences

https://kurosbio.com/
Last activity: 14.08.2025
Active
Categories: DevelopmentFinTechHealthTechMedtechProductResearchScienceSocietyTechnologyWebsite
Spine-related pain is taking a huge toll on our society: more bed-days, more days off work, and at a greater financial cost to westernized healthcare than any other condition. We’re on a mission to ease this burden through superior biologics for better spinal fusions. We believe that a greater quality and quantity of science holds the key to easing the burden of back surgery. Every day, we put our 150 years’ combined research experience to work in achieving this, which includes: 8 clinical trials initiated. >320 scientific papers published. >30 patent families granted. >10,000 patients successfully treated. Today, nearly 1 in 5 spinal fusions fail. But what can we do to change this situation - for the benefit of patients, surgeons and our wider society? This is the question that drives us at Kuros. Every day our team works across three continents to unlock the hidden secrets of bone healing through our research, development & technology program: Project Fusion. To deliver the ideal bone graft, we believe you need the highest quality & quantity of scientific evidence behind it. Which is why Project Fusion brings together an unprecedented blend of scientific, pre-clinical and clinical studies – all aimed at making the unpredictable…predictable. CONTACT KUROS TO FIND OUT MORE >>>>
Followers
4.05K
Mentions
32
Location: Switzerland, Zurich, Schlieren
Employees: 51-200
Total raised: $6.24M

Investors 3

Funding Rounds 1

DateSeriesAmountInvestors
16.09.2022-$6.24M-

Mentions in press and media 32

DateTitleDescription
14.08.2025Kuros achieves first ever operating profit in H1 The total group revenue reached USD 63.5 million, marking a growth of 78% compared to H1 2024. The company achieved an operating profit of USD 3.5 million in the first half of 2025, marking its first positive operating result, up from an o...
15.04.2025Kuros Biosciences reports 82% year over year increase in sales in the first three months of 2025Ad hoc announcement pursuant to Article 53 of the SIX listing rules Kuros Biosciences reports 82% year over year increase in sales in the first three months of 2025 Financial & Operational Highlights Direct MagnetOs™ sales increased by ...
11.03.2025Kuros Biosciences grows sales to CHF 75.6 million for 2024Ad-hoc announcement pursuant to Article 53 of the SIX listing rules Kuros Biosciences grows sales to CHF 75.6 million for 2024 Financial Highlights Direct MagnetOs™ sales increased by 136% to CHF 74.8 million (2023: CHF 31.7 million)Total M...
16.09.2022Kuros Biosciences raises CHF 6.0 million in private placement
02.06.2022Kuros Biosciences: Completion of the Acquisition of Checkmate Pharmaceuticals by Regeneron Pharmaceuticals Triggers a $5 Million Milestone PaymentAd-hoc announcement pursuant to Article 53 of the SIX listing rules • $2.5 million of milestone to be paid to XOMA Corporation under royalty agreement SCHLIEREN (ZURICH), Switzerland, June 02, 2022 (GLOBE NEWSWIRE) -- Kuros Biosciences AG (...
03.02.2022Kuros Biosciences's MagnetOs Granules cleared by FDA for expanded spinal indicationsKuros Biosciences AG / Key word(s): Miscellaneous Kuros Biosciences's MagnetOs Granules cleared by FDA for expanded spinal indications 03.02.2022 / 07:00 Rare clearance for bone graft for standalone use in spine based on human clinical data...
03.02.2022Kuros Biosciences : Press Release, 3 February 2022Kuros Biosciences's MagnetOs Granules cleared by FDA for expanded spinal indications Rare clearance for bone graft for standalone use in spine based on human clinical data Clearance attained with evidence from Level 1 randomized controlled ...
03.02.2022Kuros Biosciences's MagnetOs Granules Cleared by FDA for Expanded Spinal IndicationsRare clearance for bone graft for standalone use in spine based on human clinical dataClearance attained with evidence from Level 1 randomized controlled trialPositions MagnetOs above most other 510(k)-cleared bone grafts on the market SCHL...
03.02.2022Kuros Biosciences’s MagnetOs Granules Cleared by FDA for Expanded Spinal IndicationsRare clearance for bone graft for standalone use in spine based on human clinical dataClearance attained with evidence from Level 1 randomized controlled trialPositions MagnetOs above most other 510(k)-cleared bone grafts on the market SCHL...
26.10.2021Kuros Biosciences Reports Continued Increase in MagnetOs U.S. SalesMagnetOs U.S. YTD sales increase 119% in 2021 compared to 2020 Kuros expanding MagnetOs range to increase perioperative solutions for surgeons SCHLIEREN (ZURICH), Switzerland, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Kuros Biosciences (“Kuros” or ...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In